Aptamer Group PLC
LSE:APTA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
A
|
Aptamer Group PLC
LSE:APTA
|
23.6m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
72.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
Aptamer Group PLC
Glance View
Aptamer Group Plc operates as a biotechnology company. The firm provides custom Optimer selection and development services. The firm provides transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. The firm has developed a proprietary platform technology that drives three distinct businesses: Aptamer solutions for custom Optimer development, Aptamer diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer therapeutics for the development of Optimer-based therapeutics. Optimer can act as agonists, antagonists or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Aptamer Group PLC is 48.1%, which is above its 3-year median of 29.8%.
Over the last 2 years, Aptamer Group PLC’s Gross Margin has increased from 30.8% to 48.1%. During this period, it reached a low of -11.9% on Dec 31, 2023 and a high of 52.9% on Dec 31, 2024.
